Exact Sciences bought the rights to Freenome's blood-based colon cancer test. The news could spark Exact Sciences stock.

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Wednesday reported a loss of $1.2 million in its second quarter. The Madison, Wisconsin-based company said it had a loss of 1 ...

Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm Freenome ...

Exact Sciences’ gross margin for the quarter was 69%, with adjusted gross margin at 72%. The company reported operating cash flow of $89 million and free cash flow of $47 million, ending the quarter ...

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting earnings this Wednesday after market close.

Analysts anticipate Exact Sciences to report an earnings per share (EPS) of $0.02. Anticipation surrounds Exact Sciences's ...

The Cologuard Plus test is being offered as an in-network service to eligible Humana Medicare Advantage members.

Key Points Exact Sciences has the potential to be a big name in cancer testing and screening in the future. It already has multiple tests, and is working on one that can screen for multiple cancers.

First, more providers than ever are now prescribing Cologuard. Exact Sciences recently reported that around 147,000 providers have adopted the DNA cancer test, which reflects a CAGR of 76% since 2014.

Exact Sciences Corporation EXAS is well poised for growth in the coming quarters, led by strong Cologuard growth. The raised 2023 guidance is a major upside. However, mounting expenses and stiff ...

Last year, Exact Sciences burned through $223.6 million in cash just from its day-to-day operations. And that was a significant increase from the $102.2 million it used up in the previous year.